Budesonide/formoterol in a single inhaler (Symbicort®) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months
This open, multinational, randomised, parallel-group, six-month extension conducted in the Swedish centres of a previous six-month study compared the costs of a total of 12 months of treatment with budesonide/formoterol in a single inhaler with budesonide plus formoterol separate inhalers in 320 adults with asthma. Patients received budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5 mg deliver